Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects
about
Basal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical TherapiesOpportunities in low-level radiocarbon microtracing: applications and new technologyA survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directionsApplication of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data.Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.Basal cell carcinoma: a paradigm for targeted therapies.Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.Emerging drugs and combination strategies for basal cell carcinoma.Discovery and preclinical development of vismodegib.Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers.Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma.Adding value through accelerator mass spectrometry-enabled first in human studies.Mechanistic investigations into the species differences in pinometostat clearance: impact of binding to alpha-1-acid glycoprotein and permeability-limited hepatic uptake.Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice.The synthesis of [(14) C]AZD5122. Incorporation of an IV (14) C-microtracer dose into a first in human study to determine the absolute oral bioavailability of AZD5122.Application of (14)C-accelerator MS in pharmaceutical development.Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
P2860
Q26744173-8DE2104E-5AC0-4411-A00B-FFC492E1DCE9Q28817904-A0FBEE4E-BF6E-420F-8959-DB43A52D83B2Q30491777-63112FE9-1050-46A2-B7B0-289E1F7C670BQ30909557-F1534832-CC69-427C-BB2D-4F68568366A3Q36906428-2CCC69DB-D70C-479F-BDBD-9B9D5C589FADQ37038172-98CA11E8-FE55-4884-8017-9A1D57C25514Q38105172-8A9DFC33-83F7-46B1-AD4E-32B5DCA49ADBQ38164659-11787E9D-4C30-4492-AA84-38BCA4BAC3B9Q38207707-1E6A3910-F69A-4509-9BCD-5FDE916A57B0Q38214255-1E61C306-ADDD-43CC-A0E9-C644429576B6Q38527478-4205B339-498A-4C07-B7E4-1030172E29A9Q38842917-18978D4B-7C53-474A-9941-CEAEF442EA5EQ39573778-94F8E089-C6CB-4799-AB36-CDB1E764B2E9Q39782124-3ADC9C3D-74A3-4F85-9238-2A5159746213Q51000204-1D3D97E6-D51D-4925-B811-E549E58F1891Q53159210-79679F07-71B3-4141-BBD9-FBD3F8F9428AQ53226670-3F3B739C-4D6B-4FFE-8856-EC0C4D43D5AAQ55022663-B88B3037-58D2-4CE5-9D46-FF232A766F29
P2860
Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Single and multiple dose intra ...... gib in healthy female subjects
@ast
Single and multiple dose intra ...... gib in healthy female subjects
@en
type
label
Single and multiple dose intra ...... gib in healthy female subjects
@ast
Single and multiple dose intra ...... gib in healthy female subjects
@en
prefLabel
Single and multiple dose intra ...... gib in healthy female subjects
@ast
Single and multiple dose intra ...... gib in healthy female subjects
@en
P2093
P2860
P1476
Single and multiple dose intra ...... gib in healthy female subjects
@en
P2093
Bert L Lum
Cornelis E C A Hop
Dawn Colburn
Ilsung Chang
Jennifer A Low
Marie T Borin
Mark J Dresser
Richard A Graham
Vikram Malhi
P2860
P304
P356
10.1111/J.1365-2125.2012.04281.X
P407
P50
P577
2012-11-01T00:00:00Z